Photosensitivity reaction associated with selective serotonin re‐uptake inhibitors: Possible cross‐sensitivity?

Cheng, Ying‐Chih; Huang, Ming‐Chyi

doi:10.1111/pcn.12114

Cited by 3 publications

(3 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Observations from this study may be useful for clinical decision-making 22 especially by indicating potential for cross-reactivity amongst the medicines. 9,39 Moreover, the study confirms previously reported CADR types in addition to highlighting the factors associated with the reported CADRs in these psychiatric patients with real-world usage of SSRIs/SNRIs.…”

Section: E18supporting

confidence: 86%

“…Though not conclusive, this study's finding suggests that further post-marketing surveillance studies are required to further explore these highlighted observations. The possible severity of some of the CADRs and the crossreactivity of some of these medicines 9,39 in a vulnerable population makes this a worthwhile endeavour given that CADRs occur in 2%-5% of patients on psychiatric medications 13 and may lead to poor quality of life and consequently poor treatment adherence. 20…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Selective serotonin reuptake inhibitor and serotonin‐norepinephrine reuptake inhibitor associated cutaneous adverse drug reactions: A systematic review of case reports and case series

et al. 2021

View full text Add to dashboard Cite

Anecdotal evidence suggests that selective serotonin reuptake inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitors (SNRIs) cause cutaneous adverse drug reactions (CADRs). However, there is limited information on the factors associated with these occurrences. In this study, we aimed to describe the demographic, clinical and pharmacological characteristics associated with CADRs encountered by patients administered SSRIs and/or SNRIs for psychiatric diagnoses and to compare the differences in these factors between severe and nonsevere CADRs. A protocol was developed a priori (PROSPERO: CRD42020204830) in line with the PRISMA guidelines. We searched PubMed/Medline, PsycINFO and SCOPUS from inception to October 2020 to identify case reports and/or case series of SSRI and SNRI associated CADRs. Additional cases were obtained from the retrieved articles' bibliography. A total of 141 articles were included in the study, documenting 173 CADRs. Females accounted for 128 (74.0%) of the analysed CADRs. The median age of the cases was 42 IQR (27; 53) with no statistically significant differences in age between males and females (P = 0.542). A total of 157 (90.8%) of the reported CADRs were associated with SSRIs, particularly fluoxetine 68 (39.5%), sertraline 30 (17.4%) and paroxetine 25 (14.5%). Non-severe CADRs and severe CADRs accounted for 23 (13.4%) and 149 (86.6%) reports respectively. No statistically significant differences were observed for gender (P = 0.616), age at onset (P = 0.493) and time to onset (P = 0.105) between non-severe CADRs and SCARs. In conclusion, CADRs following SSRIs and SNRIs disproportionately affect females in the reproductive age group compared to males and are mostly associated with SSRIs. Abbreviations: AGEP acute generalised exanthematous pustulosis CADRs cutaneous adverse drug reactions MDD major depressive disorders SNRIs serotonin and norepinephrine reuptake inhibitors SSRIs selective serotonin reuptake inhibitors TCAs tricyclic antidepressants

show abstract

Section: E18supporting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

Selective serotonin reuptake inhibitor and serotonin‐norepinephrine reuptake inhibitor associated cutaneous adverse drug reactions: A systematic review of case reports and case series

et al. 2021

View full text Add to dashboard Cite

show abstract

“…9 There are cases of hyperpigmentation caused by olanzapine, an atypical antipsychotic used both for schizophrenia and for depressive episodes associated with bipolar disorder, although cutaneous reactions are very rare. 38,39 There are also reported cases caused by serotonin reuptake inhibitors 40 and by levodopa and methyldopa. 41 Finally, there are also cases of hyperpigmentation produced by benzodiazepines, such as clonazepam 29 (Figure 3).…”

Section: Psychoactive Agentsmentioning

confidence: 99%

Drug-Induced Hyperpigmentation: Review and Case Series

García

Carrasco-Molina

2019

J Am Board Fam Med

View full text Add to dashboard Cite

Background: Hyperpigmentation is a common dermatologic problem that may have substantial impact on the patient, since it affects the appearance and quality of life, and may influence treatment adherence. There are few studies of drug-induced hyperpigmentation. Methods: We studied drug-induced hyperpigmentation in patients attending an outpatient dermatology clinic in the Western Area of Valladolid (Spain) from August 1, 2017 to April 20, 2018. Results: The incidence of drug-induced hyperpigmentation was 1.31% in patients attending a first dermatology consultation in the study period. Of the 16 patients, 8 were taking more than 1 drug. The most frequent drugs identified were nonsteroidal anti-inflammatory agents (25%), antihypertensive agents (18.75%), antimalarials (12.5%), antibiotics, antineoplastic agents, psychoactive agents, simvastatin, allopurinol, amiodarone and mucolytic (6.25% each). Hyperpigmentation was found in the mucosa in 25% of patients and in photograph-exposed areas in 37.5%. Discussion: Diagnosing drug-induced hyperpigmentation is a dermatologic challenge. A differential diagnosis with hyperpigmentation caused by endocrine and metabolic disorders, the most closely-related disorders to drug-induced hyperpigmentation, and with hyperpigmentation of idiopathic origin, should be conducted. Drug-induced hyperpigmentation is a relatively frequent reason for consultation, especially in polypharmacy patients. The sample may have been biased as many patients receiving treatments frequently associated with drug-induced hyperpigmentation, such as antineoplastic drugs, are diagnosed and treated by other specialties, such as oncologists. Conclusion: Family physicians and specialists should consider drugs as a cause of hyperpigmentation to facilitate the correct diagnosis and treatment.

show abstract

Escitalopram/fluvoxamine/fluoxetine

2014

Reactions Weekly

View full text Add to dashboard Cite

Photosensitivity reaction associated with selective serotonin re‐uptake inhibitors: Possible cross‐sensitivity?

Cited by 3 publications

References 4 publications

Selective serotonin reuptake inhibitor and serotonin‐norepinephrine reuptake inhibitor associated cutaneous adverse drug reactions: A systematic review of case reports and case series

Selective serotonin reuptake inhibitor and serotonin‐norepinephrine reuptake inhibitor associated cutaneous adverse drug reactions: A systematic review of case reports and case series

Drug-Induced Hyperpigmentation: Review and Case Series

Escitalopram/fluvoxamine/fluoxetine

Contact Info

Product

Resources

About